Atezolizumab and bevacizumab in hepatocellular carcinoma

David Bomze; Tomer Meirson; Daniel Azoulay

doi:10.1056/NEJMc2021840

Atezolizumab and bevacizumab in hepatocellular carcinoma

David Bomze^*, Tomer Meirson, Daniel Azoulay

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	693-694
Number of pages	2
Journal	New England Journal of Medicine
Volume	383
Issue number	7
DOIs	https://doi.org/10.1056/NEJMc2021840
State	Published - 13 Aug 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMc2021840

Cite this

@article{2a1fe122a0564a8f9564f6c683aeaa2d,

title = "Atezolizumab and bevacizumab in hepatocellular carcinoma",

author = "David Bomze and Tomer Meirson and Daniel Azoulay",

year = "2020",

month = aug,

day = "13",

doi = "10.1056/NEJMc2021840",

language = "אנגלית",

volume = "383",

pages = "693--694",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "7",

}

TY - JOUR

T1 - Atezolizumab and bevacizumab in hepatocellular carcinoma

AU - Bomze, David

AU - Meirson, Tomer

AU - Azoulay, Daniel

PY - 2020/8/13

Y1 - 2020/8/13

UR - http://www.scopus.com/inward/record.url?scp=85089408128&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2021840

DO - 10.1056/NEJMc2021840

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 32786198

AN - SCOPUS:85089408128

SN - 0028-4793

VL - 383

SP - 693

EP - 694

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 7

ER -

Atezolizumab and bevacizumab in hepatocellular carcinoma

UN SDGs

Access to Document

Other files and links

Cite this